Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-1,353
Closed -$50.9K 288
2023
Q4
$50.9K Buy
1,353
+20
+2% +$611 0.03% 114
2023
Q3
$37.1K Buy
1,333
+16
+1% +$501 0.02% 128
2023
Q2
$39.8K Buy
1,317
+17
+1% +$497 0.03% 129
2023
Q1
$40.1K Hold
1,300
0.03% 125
2022
Q4
$48.8K Buy
+1,300
New +$51.6K 0.04% 106

Other funds holding SNV

MB, Levis & Associates's SNV Position: Q1 2024 in Review

MB, Levis & Associates sold out of Synovus (SNV) in Q1 2024, closing a stake of 1,353 shares — an estimated $50.9K sold.

MB, Levis & Associates first reported a position in SNV in Q4 2022 and held it in 5 quarters. The position peaked at $50.9K in Q4 2023. 408 funds tracked by Wall St. Rank hold SNV as of Q1 2024.

  • MB, Levis & Associates reported no remaining Synovus position as of Q1 2024 after selling out during the quarter.
  • MB, Levis & Associates sold 1,353 Synovus shares in Q1 2024, an estimated $50.9K.
  • MB, Levis & Associates first reported a position in Synovus in Q4 2022 and held it in 5 quarters.
  • MB, Levis & Associates's Synovus position peaked at $50.9K in Q4 2023.
  • 408 funds tracked by Wall St. Rank held Synovus as of Q1 2024.

Based on MB, Levis & Associates's 13F filing for Q1 2024, filed 7 May 2025.